These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 29439912

  • 1. [Pruritus and rivaroxaban].
    Aguilar-Shea AL, Gallardo-Mayo C.
    Semergen; 2018; 44(4):e96-e97. PubMed ID: 29439912
    [No Abstract] [Full Text] [Related]

  • 2. [Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: A retrospective analysis of the rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)].
    Divisón Garrote JA, Escobar Cervantes C.
    Semergen; 2016; 42(4):260-2. PubMed ID: 26653339
    [No Abstract] [Full Text] [Related]

  • 3. Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation: Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
    Orgel R, Wojdyla D, Huberman D, Halperin JL, Breithardt G, Singer DE, Fox KAA, Hankey GJ, Mahaffey KW, Jones WS, Patel MR.
    Circ Cardiovasc Qual Outcomes; 2017 May; 10(5):. PubMed ID: 28495674
    [No Abstract] [Full Text] [Related]

  • 4. Evaluation of the appropriateness of dosing, indication and safety of rivaroxaban in a community hospital.
    Tellor KB, Patel S, Armbruster AL, Daly MW.
    J Clin Pharm Ther; 2015 Aug; 40(4):447-51. PubMed ID: 26010016
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial).
    Bansilal S, Bloomgarden Z, Halperin JL, Hellkamp AS, Lokhnygina Y, Patel MR, Becker RC, Breithardt G, Hacke W, Hankey GJ, Nessel CC, Singer DE, Berkowitz SD, Piccini JP, Mahaffey KW, Fox KA, ROCKET AF Steering Committee and Investigators.
    Am Heart J; 2015 Oct; 170(4):675-682.e8. PubMed ID: 26386791
    [Abstract] [Full Text] [Related]

  • 6. Design and Rationale of the RELAXED (Recurrent Embolism Lessened by rivaroxaban, an Anti-Xa agent, of Early Dosing for acute ischemic stroke and transient ischemic attack with atrial fibrillation) Study.
    Yasaka M, Minematsu K, Toyoda K, Yamagami H, Yoshimura S, Nagao T, Mori E, Hirano T, Hamasaki T, Yamaguchi T.
    J Stroke Cerebrovasc Dis; 2016 Jun; 25(6):1342-8. PubMed ID: 26987488
    [Abstract] [Full Text] [Related]

  • 7. Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
    Chen ST, Hellkamp AS, Becker RC, Berkowitz SD, Breithardt G, Fox KAA, Hacke W, Halperin JL, Hankey GJ, Mahaffey KW, Nessel CC, Piccini JP, Singer DE, Patel MR.
    Am J Cardiol; 2017 Nov 15; 120(10):1837-1840. PubMed ID: 28886856
    [Abstract] [Full Text] [Related]

  • 8. [Nosebleed in new oral anticoagulant treatment - what should be done?].
    Stiefelhagen P.
    MMW Fortschr Med; 2015 Sep 10; 157(15):25. PubMed ID: 26349711
    [No Abstract] [Full Text] [Related]

  • 9. Reversal of rivaroxaban anticoagulation by nonactivated prothrombin complex concentrate in urgent surgery.
    Chic Acevedo C, Velasco F, Herrera C.
    Future Cardiol; 2015 Sep 10; 11(5):525-9. PubMed ID: 26090568
    [Abstract] [Full Text] [Related]

  • 10. Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis.
    Lindner SM, Fordyce CB, Hellkamp AS, Lokhnygina Y, Piccini JP, Breithardt G, Mahaffey KW, Singer DE, Hacke W, Halperin JL, Hankey GJ, Berkowitz SD, Nessel CC, Becker RC, Fox KA, Patel MR, ROCKET AF Steering Committee and Investigators.
    Circulation; 2017 Mar 07; 135(10):1001-1003. PubMed ID: 28264892
    [No Abstract] [Full Text] [Related]

  • 11. Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation.
    Piccini JP, Hellkamp AS, Washam JB, Becker RC, Breithardt G, Berkowitz SD, Halperin JL, Hankey GJ, Hacke W, Mahaffey KW, Nessel CC, Singer DE, Fox KA, Patel MR.
    Circulation; 2016 Jan 26; 133(4):352-60. PubMed ID: 26673560
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AF.
    Barnett AS, Cyr DD, Goodman SG, Levitan BS, Yuan Z, Hankey GJ, Singer DE, Becker RC, Breithardt G, Berkowitz SD, Halperin JL, Hacke W, Mahaffey KW, Nessel CC, Fox KAA, Patel MR, Piccini JP.
    Int J Cardiol; 2018 Apr 15; 257():78-83. PubMed ID: 29506743
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Apixaban, Rivaroxaban, and Dabigatran in Patients Undergoing Atrial Fibrillation Ablation.
    Rillig A, Lin T, Plesman J, Heeger CH, Lemes C, Metzner A, Mathew S, Wissner E, Wohlmuth P, Ouyang F, Kuck KH, Tilz RR.
    J Cardiovasc Electrophysiol; 2016 Feb 15; 27(2):147-53. PubMed ID: 26464027
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation.
    Beyer-Westendorf J, Ehlken B, Evers T.
    Europace; 2016 Aug 15; 18(8):1150-7. PubMed ID: 26830891
    [Abstract] [Full Text] [Related]

  • 18. Direct oral anticoagulants are effective and safe in the treatment of venous thromboembolism and atrial fibrillation in morbidly obese patients.
    Mohamed MFH, Elewa H, Mubasher M, Danjuma M.
    J Thromb Thrombolysis; 2021 Apr 15; 51(3):701-702. PubMed ID: 32737742
    [No Abstract] [Full Text] [Related]

  • 19. [Real life clinical management of nonvalvular atrial fibrillation: results from the Italian epidemiological survey eXperience on the use of rivaroxaban].
    Colonna P, Ammirati F, a nome del Gruppo Italiano eXperience.
    G Ital Cardiol (Rome); 2016 Nov 15; 17(11):932-939. PubMed ID: 27996999
    [Abstract] [Full Text] [Related]

  • 20. Optimal dosing of rivaroxaban is undefined.
    Moore TJ.
    BMJ; 2016 Oct 18; 355():i5549. PubMed ID: 27756735
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.